John Lin, MD
Urology · Gilbert, AZNPI 1467494435
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,200 of the $107,679 with a category attached, or 65.2%. Neotract Inc. accounts for 95.2% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $77,830 and has fallen 98.2% since, to $1,370 in 2025. Among urology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $443.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$102K
- Teleflex LLC$2K
- Calyxo, Inc.$369
- Verity Pharmaceuticals Inc.$281
- Pfizer$279
- Myriad Genetic Laboratories, Inc.$275
- plus $2K from 26 others
What the payments were for
- Consulting fees$23,35022%
- Speaking & faculty fees$70,20065%
- Travel & lodging$6,3946%
- Food & beverage$6,9376%
- Education$7981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 117 | $102,495 |
| Teleflex LLC | 33 | $2,208 |
| Calyxo, Inc. | 2 | $369 |
| Verity Pharmaceuticals Inc. | 13 | $281 |
| Pfizer | 7 | $279 |
| Myriad Genetic Laboratories, Inc. | 10 | $275 |
| Progenics Pharmaceuticals, Inc. | 6 | $271 |
| Hollister Incorporated | 9 | $223 |
| Procept Biorobotics Corporation | 3 | $148 |
| Innovation Technologies Inc | 2 | $132 |
| Medtronic | 2 | $124 |
| Boston Scientific | 3 | $112 |
| Urovant Sciences Inc | 1 | $88 |
| Astellas Pharma US Inc | 5 | $88 |
| Olympus America Inc. | 4 | $76 |
| Merck | 3 | $58 |
| Ambu Inc. | 3 | $56 |
| Coloplast | 3 | $44 |
| Angiodynamics, Inc. | 1 | $42 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Laborie Medical Technologies Corp. | 2 | $33 |
| Urogen Pharma, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Axonics, Inc. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $19 |
| Blue Earth Diagnostics | 1 | $16 |
| Immunitybio, Inc. | 1 | $16 |
| Valencia Technologies Corporation | 1 | $14 |
| SRS Medical Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,679 in reported general payments places this provider in the 95th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 42 | $40,176 |
| GemtesaVibegron | 15 | $10,211 |
| Estradiol | 61 | $4,548 |
| Tamsulosin Hcl | 215 | $3,740 |
| Finasteride | 125 | $1,661 |
| Oxybutynin Chloride | 30 | $1,069 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $378 |
| Levofloxacin | 123 | $279 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $121 |
| Ciprofloxacin Hcl | 30 | $69 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $55 |
| Diclofenac Sodium | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $88 | $40,17642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 269 urology providers in Arizona.
Other urology in Gilbert
- Chinedu MmejeGilbert$114K
- Pratik PatelGilbert$58K
- Kian AhmadiehGilbert$19K
- Frank SimonciniGilbert$11K
- Devin PatelGilbert$11K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
- Mitzi BarmatzTucson$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.